BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet's disease: A systematic literature review. Seminars in Arthritis and Rheumatism 2020;50:797-804. [DOI: 10.1016/j.semarthrit.2020.05.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Tugal-Tutkun I. Uveitis in Behçet disease - an update. Curr Opin Rheumatol 2022. [PMID: 36255985 DOI: 10.1097/BOR.0000000000000911] [Reference Citation Analysis]
2 Efthimiou P, Petryna O, Nakasato P, Kontzias A. New insights on multigenic autoinflammatory diseases. Ther Adv Musculoskelet Dis 2022;14:1759720X221117880. [PMID: 36081748 DOI: 10.1177/1759720X221117880] [Reference Citation Analysis]
3 Cui B, Jia HZ, Gao LX, Dong XF. Risk of anxiety and depression in patients with uveitis: a Meta-analysis. Int J Ophthalmol 2022;15:1381-90. [PMID: 36017044 DOI: 10.18240/ijo.2022.08.23] [Reference Citation Analysis]
4 Narazaki M, Kishimoto T. Current status and prospects of IL-6–targeting therapy. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2097905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Allaoui A, Belabbess F, Jabbouri R, Alaoui F, Naitelhou A. Entero-Behcet: A Challenging Aspect of Behcet Disease. Behçet's Disease - Recent Advances and New Perspectives [Working Title] 2022. [DOI: 10.5772/intechopen.105164] [Reference Citation Analysis]
6 CNS Syndromes at the Frontier of Autoimmune Encephalitis. Autoimmune Encephalitis and Related Disorders of the Nervous System 2022. [DOI: 10.1017/9781108696722.019] [Reference Citation Analysis]
7 van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behçet's disease and treatment modalities. Semin Arthritis Rheum 2022;52:151956. [PMID: 35038644 DOI: 10.1016/j.semarthrit.2022.151956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 de Jesus Guimarães C, da Silva Costa PM, de Brito Vieira Neto J, Guimarães AC. Chemotherapy for Rheumatology. The Golden Guide to Oncologic Pharmacy 2022. [DOI: 10.1007/978-3-030-98596-7_16] [Reference Citation Analysis]
9 Mondal S, Ghosh A. Off-Label Use of Biologics in Rheumatological Disorders. Handbook of Biologics for Rheumatological Disorders 2022. [DOI: 10.1007/978-981-16-7200-2_25] [Reference Citation Analysis]
10 Higashida-Konishi M, Akiyama M, Shimada T, Hama S, Takei H, Izumi K, Oshima H, Okano Y. Acute Encephalitis in Primary Sjögren's Syndrome: A Case Report and Literature Review. Mod Rheumatol Case Rep 2021:rxab042. [PMID: 34850084 DOI: 10.1093/mrcr/rxab042] [Reference Citation Analysis]
11 Arbrile M, Radin M, Rossi D, Menegatti E, Baldovino S, Sciascia S, Roccatello D. Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. Front Immunol 2021;12:769785. [PMID: 34759935 DOI: 10.3389/fimmu.2021.769785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Han MM, Yuan XR, Shi X, Zhu XY, Su Y, Xiong DK, Zhang XM, Zhou H, Wang JN. The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases. Front Pharmacol 2021;12:732790. [PMID: 34539413 DOI: 10.3389/fphar.2021.732790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
13 Kaneko Y, Takeuchi T. An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine 2021;146:155645. [PMID: 34303949 DOI: 10.1016/j.cyto.2021.155645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ozguler Y, Ozdede A, Hatemi G. Recent Insights into the Management of Behçet Syndrome. J Inflamm Res 2021;14:3429-41. [PMID: 34321904 DOI: 10.2147/JIR.S285400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Louthrenoo W. Behcet’s Disease in Southeast Asia. Clinical Features, Genetic Study, and Review of Recent Treatment. Journal of Clinical Rheumatology and Immunology 2021;21:22-36. [DOI: 10.1142/s2661341721300020] [Reference Citation Analysis]
16 Gueudry J, Leclercq M, Saadoun D, Bodaghi B. Old and New Challenges in Uveitis Associated with Behçet's Disease. J Clin Med 2021;10:2318. [PMID: 34073249 DOI: 10.3390/jcm10112318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Choong DJ, Tan E. Does tocilizumab have a role in dermatology? A review of clinical applications, its adverse side effects and practical considerations. Dermatol Ther 2021;34:e14990. [PMID: 34004074 DOI: 10.1111/dth.14990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Alibaz-Oner F, Direskeneli H. Advances in the Treatment of Behcet's Disease. Curr Rheumatol Rep 2021;23:47. [PMID: 34014377 DOI: 10.1007/s11926-021-01011-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
19 Espinosa G, Carballeira MR. Enfermedad de Behçet. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1975-1984. [DOI: 10.1016/j.med.2021.05.010] [Reference Citation Analysis]
20 Eroglu DS, Colaklar A, Ceran A, Sezer S, Torgutalp M, Kinikli G. Behçet’s Syndrome Complicated with Pulmonary Artery Thrombosis: Response to Tocilizumab Treatment. Aktuelle Rheumatologie 2021;46:485-8. [DOI: 10.1055/a-1400-2586] [Reference Citation Analysis]
21 Uygunoglu U, Siva A. An uncommon disease included commonly in the differential diagnosis of neurological diseases: Neuro-Behçet's syndrome. J Neurol Sci 2021;426:117436. [PMID: 33984547 DOI: 10.1016/j.jns.2021.117436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Rodríguez-Carrio J, Nucera V, Masala IF, Atzeni F. Behçet disease: From pathogenesis to novel therapeutic options. Pharmacol Res 2021;167:105593. [PMID: 33826948 DOI: 10.1016/j.phrs.2021.105593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
23 Suzuki E, Kanno T, Oda R, Kobashi R, Imamura H, Odajima H, Furuya MY, Migita K. Effectiveness of tocilizumab for Behcet disease complicated by amyloidosis in the intestinal tract. Medicine: Case Reports and Study Protocols 2020;1:e0022. [DOI: 10.1097/md9.0000000000000022] [Reference Citation Analysis]
24 Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. Ann Hematol 2020;99:2463-75. [DOI: 10.1007/s00277-020-04275-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Ann Rheum Dis 2020:annrheumdis-2020-218710. [PMID: 32907804 DOI: 10.1136/annrheumdis-2020-218710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]